Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | STAT1 | P42224 | 2/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876706 | 0.89 | RAB9A (0.60) | DGAT1ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL4876207 | 0.85 | PTPN1 (0.54) | DGAT1ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL4876062 | 0.82 | KDM4E (0.52) | DGAT1ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL1250427 | 0.80 | DGAT1 (1.00) | DGAT1ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL6251713 | 0.73 | RAB9A (0.71) | DGAT1ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL2884316 | 0.73 | ALDH1A1 (1.00) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2457137 | 0.72 | RAB9A (0.67) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL13680597 | 0.70 | ALDH1A1 (0.55) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL27074034 | 0.69 | NPC1 (0.57) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL29231579 | 0.69 | ALOX15 (0.82) | DGAT1ALDH1A1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | claimed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | claimed |
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | DGAT1 2890/4885ALDH1A1 404/4885NPC1 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.